AstraZeneca chops 210 workers, closes sites as it looks to concentrate biologics manufacturing in one place
AstraZeneca is closing down two manufacturing sites in Colorado that collectively employed 210 workers, in an apparent effort to consolidate its biologics supply chain.
First reported in a WARN notice on Tuesday, the layoffs are “unrelated” to the organizational changes announced a day prior, spokesperson Michele Meixell told me in an email.
The closure of Boulder and Longmont is simply a decision to consolidate the biologics manufacturing network in one large-scale drug substance facility (our site currently operating in Frederick, MD) in order to improve efficiency in our global biologics supply chain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.